MESOBLAST LIMITED - Announcements

0.44%

$2.30

Market Cap $2.943B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

MSB	Notification of cessation of securities - MSB		16/10/23	22.14KB	Share
MSB	Notification regarding unquoted securities - MSB		16/10/23	25.52KB	Share
MSB	Final Director's Interest Notice		29/09/23	289.13KB	Share
MSB	Jane Bell Appointed Chair of Audit and Risk Committee		26/09/23	133KB	Share
MSB	Mesoblast Type A Meeting with FDA		21/09/23	180.71KB	Share
MSB	MSB Annual Financial Results and Operational Update	PRICE SENSITIVE	31/08/23	430.53KB	Share
MSB	Annual Financial Results Presentation		31/08/23	1.55MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	31/08/23	2.9MB	Share
MSB	Mesoblast 2023 Full Year Financial Results Webcast		29/08/23	113.86KB	Share
MSB	Change in substantial holding		29/08/23	982.31KB	Share
MSB	Ceasing to be a substantial holder		11/08/23	386.68KB	Share
MSB	Ceasing to be a substantial holder		10/08/23	382.31KB	Share
MSB	Change in substantial holding		10/08/23	477.4KB	Share
MSB	Change in substantial holding		09/08/23	463.15KB	Share
MSB	Change in substantial holding		09/08/23	481.52KB	Share
MSB	Update on BLA for Graft Versus Host Disease	PRICE SENSITIVE	04/08/23	178.56KB	Share
MSB	Change in substantial holding		03/08/23	560.83KB	Share
MSB	Trading Halt	PRICE SENSITIVE	02/08/23	195.14KB	Share
MSB	Change in substantial holding		01/08/23	538.92KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	401.67KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Ys		07/07/23	566.38KB	Share
MSB	Change of Director's Interest Notice		13/06/23	259.12KB	Share
MSB	Mesoblast Director Appointed to Strategic Advisory Role		05/06/23	161.1KB	Share
MSB	MSB Reports Q3 Financial Results and Operational Highlights	PRICE SENSITIVE	26/05/23	402.9KB	Share
MSB	Third Quarter Results Presentation		26/05/23	1.76MB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	26/05/23	591.58KB	Share
MSB	Mesoblast Third Quarter Financial Results Webcast		24/05/23	114.98KB	Share
MSB	Becoming a substantial holder		03/05/23	842.89KB	Share
MSB	Change in substantial holding		03/05/23	245.59KB	Share
MSB	Cleansing Notice		01/05/23	232.25KB	Share
MSB	Application for quotation of securities - MSB		28/04/23	23.26KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	416.6KB	Share
MSB	Reinstatement to Official Quotation	PRICE SENSITIVE	26/04/23	86.01KB	Share
MSB	Proposed issue of securities - MSB		26/04/23	24.49KB	Share
MSB	Mesoblast Completes Private Placement	PRICE SENSITIVE	26/04/23	169.21KB	Share
MSB	Voluntary Suspension	PRICE SENSITIVE	24/04/23	281.47KB	Share
MSB	Trading Halt	PRICE SENSITIVE	20/04/23	281.84KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	20/04/23	115.82KB	Share
MSB	FDA Schedules GvHD Pre-License Manufacturing Inspection		22/03/23	187.07KB	Share
MSB	Appendix 3G and Appendix 3H		15/03/23	652.68KB	Share
MSB	FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L	PRICE SENSITIVE	08/03/23	195.02KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	08/03/23	114.29KB	Share
MSB	Prospectus for Warrants Related to Oaktree Facility		03/03/23	509.39KB	Share
MSB	DREAM HF Trial Published in JACC	PRICE SENSITIVE	28/02/23	226.95KB	Share
MSB	MSB Q2 Financial Results and Operational Highlights	PRICE SENSITIVE	28/02/23	408.95KB	Share
MSB	Second Quarter Results Presentation		28/02/23	1.57MB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.67MB	Share
MSB	Mesoblast Second Quarter Financial Results Webcast		27/02/23	115.2KB	Share
MSB	Remestemcel Clinical and Potency Studies Presented at Tandem		17/02/23	175.63KB	Share
MSB	FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP		09/02/23	187.83KB	Share
MSB	Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD	PRICE SENSITIVE	01/02/23	195.59KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	419.11KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Ys		16/01/23	575.59KB	Share
MSB	Biotech Showcase 2023 Presentation in San Francisco		10/01/23	1.67MB	Share
MSB	Extension of Undrawn US$30 million Facility	PRICE SENSITIVE	23/12/22	161.36KB	Share
MSB	Proposed issue of securities - MSB		23/12/22	25.9KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Y		02/12/22	582.16KB	Share
MSB	Amended Constitution		24/11/22	626.04KB	Share
MSB	Results of Meeting		23/11/22	187.96KB	Share
MSB	Chairman's Address to Shareholders		23/11/22	192.3KB	Share
MSB	Long-Term Survival for Acute GvHD Treatment with Remestemcel	PRICE SENSITIVE	23/11/22	189.85KB	Share
MSB	MSB Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	23/11/22	439.61KB	Share
MSB	CEO First Quarter Results and 2022 AGM Presentation		23/11/22	2.06MB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	23/11/22	500.21KB	Share
MSB	Mesoblast First Quarter Financial Results Webcast		21/11/22	113.78KB	Share
MSB	Removal of Amendment to Constitution About Virtual Meetings		15/11/22	123.99KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	419.32KB	Share
MSB	Notice of Annual General Meeting and Proxy Form		24/10/22	443.56KB	Share
MSB	Annual Report to Shareholders		24/10/22	6.59MB	Share
MSB	Appendix 4G and Corporate Governance Statement		24/10/22	412.08KB	Share
MSB	Notification of cessation of securities - MSB		14/10/22	21.69KB	Share
MSB	Submits New Information to FDA IND File for SR-aGVHD	PRICE SENSITIVE	03/10/22	168.87KB	Share
MSB	Change of Director's Interest Notice		20/09/22	229.59KB	Share
MSB	Change of Director's Interest Notice		12/09/22	226.98KB	Share
MSB	MSB Annual Financial Results and Operational Highlights	PRICE SENSITIVE	31/08/22	386.1KB	Share
MSB	Annual Financial Results Presentation		31/08/22	1.83MB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	31/08/22	3.16MB	Share
MSB	Mesoblast 2022 Full Year Financial Results Webcast		30/08/22	116.05KB	Share
MSB	Director Appointment		18/08/22	133.74KB	Share
MSB	Initial Director's Interest Notice		18/08/22	305.67KB	Share
MSB	Final Director's Interest Notice		18/08/22	220.39KB	Share
MSB	Ceasing to be a substantial holder - Tiga Trading Pty Ltd		16/08/22	306.57KB	Share
MSB	Ceasing to be a substantial holder from TEK		16/08/22	324.86KB	Share
MSB	Ceasing to be a substantial holder from TOP		16/08/22	320.64KB	Share
MSB	Change in substantial holding		16/08/22	491.21KB	Share
MSB	Cleansing Notice		12/08/22	176.58KB	Share
MSB	Appendix 2A		12/08/22	357.17KB	Share
MSB	Appendix 3B		09/08/22	652.66KB	Share
MSB	US$45 Million Private Placement to Major Shareholders	PRICE SENSITIVE	09/08/22	157.61KB	Share
MSB	Reinstatement to Quotation	PRICE SENSITIVE	09/08/22	85.62KB	Share
MSB	Voluntary Suspension	PRICE SENSITIVE	08/08/22	221.75KB	Share
MSB	Trading Halt	PRICE SENSITIVE	04/08/22	206.88KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	04/08/22	116.13KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	444.42KB	Share
MSB	Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE	PRICE SENSITIVE	19/07/22	185.89KB	Share
MSB	Appendix 3H and Appendix 3Y		14/07/22	350.16KB	Share
MSB	Rexlemestrocel-L to be Highlighted on Heart Failure Panel		12/07/22	167.56KB	Share
MSB	Mesoblast CLBP Event with Key Opinion Leaders		21/06/22	168.79KB	Share
MSB	Chronic Low Back Pain KOL Event Presentation		21/06/22	6.92MB	Share
MSB	Litigation Update		14/06/22	172.01KB	Share

MSB Notification of cessation of securities - MSB
16/10/23		22.14KB	Share
MSB Notification regarding unquoted securities - MSB
16/10/23		25.52KB	Share
MSB Final Director's Interest Notice
29/09/23		289.13KB	Share
MSB Jane Bell Appointed Chair of Audit and Risk Committee
26/09/23		133KB	Share
MSB Mesoblast Type A Meeting with FDA
21/09/23		180.71KB	Share
MSB MSB Annual Financial Results and Operational Update
31/08/23	PRICE SENSITIVE	430.53KB	Share
MSB Annual Financial Results Presentation
31/08/23		1.55MB	Share
MSB Preliminary Final Report including Appendix 4E
31/08/23	PRICE SENSITIVE	2.9MB	Share
MSB Mesoblast 2023 Full Year Financial Results Webcast
29/08/23		113.86KB	Share
MSB Change in substantial holding
29/08/23		982.31KB	Share
MSB Ceasing to be a substantial holder
11/08/23		386.68KB	Share
MSB Ceasing to be a substantial holder
10/08/23		382.31KB	Share
MSB Change in substantial holding
10/08/23		477.4KB	Share
MSB Change in substantial holding
09/08/23		463.15KB	Share
MSB Change in substantial holding
09/08/23		481.52KB	Share
MSB Update on BLA for Graft Versus Host Disease
04/08/23	PRICE SENSITIVE	178.56KB	Share
MSB Change in substantial holding
03/08/23		560.83KB	Share
MSB Trading Halt
02/08/23	PRICE SENSITIVE	195.14KB	Share
MSB Change in substantial holding
01/08/23		538.92KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	401.67KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Ys
07/07/23		566.38KB	Share
MSB Change of Director's Interest Notice
13/06/23		259.12KB	Share
MSB Mesoblast Director Appointed to Strategic Advisory Role
05/06/23		161.1KB	Share
MSB MSB Reports Q3 Financial Results and Operational Highlights
26/05/23	PRICE SENSITIVE	402.9KB	Share
MSB Third Quarter Results Presentation
26/05/23		1.76MB	Share
MSB Third Quarter Financial Results on Form 6-K
26/05/23	PRICE SENSITIVE	591.58KB	Share
MSB Mesoblast Third Quarter Financial Results Webcast
24/05/23		114.98KB	Share
MSB Becoming a substantial holder
03/05/23		842.89KB	Share
MSB Change in substantial holding
03/05/23		245.59KB	Share
MSB Cleansing Notice
01/05/23		232.25KB	Share
MSB Application for quotation of securities - MSB
28/04/23		23.26KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	416.6KB	Share
MSB Reinstatement to Official Quotation
26/04/23	PRICE SENSITIVE	86.01KB	Share
MSB Proposed issue of securities - MSB
26/04/23		24.49KB	Share
MSB Mesoblast Completes Private Placement
26/04/23	PRICE SENSITIVE	169.21KB	Share
MSB Voluntary Suspension
24/04/23	PRICE SENSITIVE	281.47KB	Share
MSB Trading Halt
20/04/23	PRICE SENSITIVE	281.84KB	Share
MSB Pause in Trading
20/04/23	PRICE SENSITIVE	115.82KB	Share
MSB FDA Schedules GvHD Pre-License Manufacturing Inspection
22/03/23		187.07KB	Share
MSB Appendix 3G and Appendix 3H
15/03/23		652.68KB	Share
MSB FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
08/03/23	PRICE SENSITIVE	195.02KB	Share
MSB Pause in Trading
08/03/23	PRICE SENSITIVE	114.29KB	Share
MSB Prospectus for Warrants Related to Oaktree Facility
03/03/23		509.39KB	Share
MSB DREAM HF Trial Published in JACC
28/02/23	PRICE SENSITIVE	226.95KB	Share
MSB MSB Q2 Financial Results and Operational Highlights
28/02/23	PRICE SENSITIVE	408.95KB	Share
MSB Second Quarter Results Presentation
28/02/23		1.57MB	Share
MSB Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.67MB	Share
MSB Mesoblast Second Quarter Financial Results Webcast
27/02/23		115.2KB	Share
MSB Remestemcel Clinical and Potency Studies Presented at Tandem
17/02/23		175.63KB	Share
MSB FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP
09/02/23		187.83KB	Share
MSB Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
01/02/23	PRICE SENSITIVE	195.59KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	419.11KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Ys
16/01/23		575.59KB	Share
MSB Biotech Showcase 2023 Presentation in San Francisco
10/01/23		1.67MB	Share
MSB Extension of Undrawn US$30 million Facility
23/12/22	PRICE SENSITIVE	161.36KB	Share
MSB Proposed issue of securities - MSB
23/12/22		25.9KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Y
02/12/22		582.16KB	Share
MSB Amended Constitution
24/11/22		626.04KB	Share
MSB Results of Meeting
23/11/22		187.96KB	Share
MSB Chairman's Address to Shareholders
23/11/22		192.3KB	Share
MSB Long-Term Survival for Acute GvHD Treatment with Remestemcel
23/11/22	PRICE SENSITIVE	189.85KB	Share
MSB MSB Q1 Financial Results and Operational Highlights
23/11/22	PRICE SENSITIVE	439.61KB	Share
MSB CEO First Quarter Results and 2022 AGM Presentation
23/11/22		2.06MB	Share
MSB First Quarter Financial Results on Form 6-K
23/11/22	PRICE SENSITIVE	500.21KB	Share
MSB Mesoblast First Quarter Financial Results Webcast
21/11/22		113.78KB	Share
MSB Removal of Amendment to Constitution About Virtual Meetings
15/11/22		123.99KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	419.32KB	Share
MSB Notice of Annual General Meeting and Proxy Form
24/10/22		443.56KB	Share
MSB Annual Report to Shareholders
24/10/22		6.59MB	Share
MSB Appendix 4G and Corporate Governance Statement
24/10/22		412.08KB	Share
MSB Notification of cessation of securities - MSB
14/10/22		21.69KB	Share
MSB Submits New Information to FDA IND File for SR-aGVHD
03/10/22	PRICE SENSITIVE	168.87KB	Share
MSB Change of Director's Interest Notice
20/09/22		229.59KB	Share
MSB Change of Director's Interest Notice
12/09/22		226.98KB	Share
MSB MSB Annual Financial Results and Operational Highlights
31/08/22	PRICE SENSITIVE	386.1KB	Share
MSB Annual Financial Results Presentation
31/08/22		1.83MB	Share
MSB Preliminary Final Report
31/08/22	PRICE SENSITIVE	3.16MB	Share
MSB Mesoblast 2022 Full Year Financial Results Webcast
30/08/22		116.05KB	Share
MSB Director Appointment
18/08/22		133.74KB	Share
MSB Initial Director's Interest Notice
18/08/22		305.67KB	Share
MSB Final Director's Interest Notice
18/08/22		220.39KB	Share
MSB Ceasing to be a substantial holder - Tiga Trading Pty Ltd
16/08/22		306.57KB	Share
MSB Ceasing to be a substantial holder from TEK
16/08/22		324.86KB	Share
MSB Ceasing to be a substantial holder from TOP
16/08/22		320.64KB	Share
MSB Change in substantial holding
16/08/22		491.21KB	Share
MSB Cleansing Notice
12/08/22		176.58KB	Share
MSB Appendix 2A
12/08/22		357.17KB	Share
MSB Appendix 3B
09/08/22		652.66KB	Share
MSB US$45 Million Private Placement to Major Shareholders
09/08/22	PRICE SENSITIVE	157.61KB	Share
MSB Reinstatement to Quotation
09/08/22	PRICE SENSITIVE	85.62KB	Share
MSB Voluntary Suspension
08/08/22	PRICE SENSITIVE	221.75KB	Share
MSB Trading Halt
04/08/22	PRICE SENSITIVE	206.88KB	Share
MSB Pause in Trading
04/08/22	PRICE SENSITIVE	116.13KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	444.42KB	Share
MSB Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
19/07/22	PRICE SENSITIVE	185.89KB	Share
MSB Appendix 3H and Appendix 3Y
14/07/22		350.16KB	Share
MSB Rexlemestrocel-L to be Highlighted on Heart Failure Panel
12/07/22		167.56KB	Share
MSB Mesoblast CLBP Event with Key Opinion Leaders
21/06/22		168.79KB	Share
MSB Chronic Low Back Pain KOL Event Presentation
21/06/22		6.92MB	Share
MSB Litigation Update
14/06/22		172.01KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.30		Change 0.010(0.44%)		Mkt cap ! $2.943B

Open	High	Low	Value	Volume
$2.26	$2.31	$2.25	$2.152M	941.9K

Buyers (Bids)

No.	Vol.	Price($)
50	38932	$2.29

Sellers (Offers)

Price($)	Vol.	No.
$2.30	51504	29

View Market Depth

No.	Vol.	Price($)
50	48239	2.290
33	150780	2.280
21	81073	2.270
13	120989	2.260
28	151380	2.250

Price($)	Vol.	No.
2.300	51479	29
2.310	55817	24
2.320	158846	23
2.330	139008	17
2.340	68677	7

Last trade - 12.54pm 12/08/2025 (20 minute delay)


Last $2.30		Change 0.010 ( 0.99 %)
Open	High	Low	Volume
$2.27	$2.31	$2.26	328099
Last updated 13.14pm 12/08/2025 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories